{
  "validated_facts": [
    {
      "drug_name": "selective serotonin reuptake inhibitors",
      "condition_name": "depression",
      "relation": "FIRST_LINE_FOR",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "abstract",
      "span": "Pharmacotherapy, especially selective serotonin reuptake inhibitors antidepressants, remains the most frequent option for treating depression during the acute phase.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "depression-focused psychotherapy",
      "condition_name": "depression",
      "relation": "MAINTENANCE_FOR",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "abstract",
      "span": "Depression-focused psychotherapy is the second most common option for helping patients overcome the acute phase, maintain remission, and prevent relapses.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "depression-focused psychotherapy",
      "condition_name": "depression",
      "relation": "PREVENTS_RELAPSE_IN",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "abstract",
      "span": "Depression-focused psychotherapy is the second most common option for helping patients overcome the acute phase, maintain remission, and prevent relapses.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "electroconvulsive therapy",
      "condition_name": "depression",
      "relation": "EFFECTIVE_IN_SUBGROUP",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "abstract",
      "span": "Electroconvulsive therapy is the most effective somatic therapy for depression in some specific situations.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "electroconvulsive therapy",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "introduction",
      "span": "Acute-phase treatment options include pharmacotherapy, depression-focused psychotherapy, combinations of medications and psychotherapy, and somatic therapies such as electroconvulsive therapy (ECT).",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "TCAs",
      "condition_name": "major depressive disorder",
      "relation": "EQUIVALENT_TO",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "TCAs",
      "span": "TCAs-such as amitriptyline, nortriptyline, protriptyline, imipramine, desipramine, doxepin, and trimipramine-are about as effective as other classes of antidepressants-including SSRIs, SNRIs, and MAOIs-in treating major depression.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "TCAs",
      "condition_name": "major depressive disorder",
      "relation": "SUPERIOR_TO",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "TCAs",
      "span": "This efficacy can be explained by the superiority of TCAs over SSRIs for patients with severe major depressive disorder (MDD) symptoms who require hospitalization.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": "hospitalized patients with severe symptoms",
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "TCAs",
      "condition_name": "major depressive disorder",
      "relation": "CONTRAINDICATED_FOR",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "TCAs",
      "span": "In most cases, TCAs should generally be reserved for situations when first-line drug treatments have failed.",
      "confidence": 0.8,
      "treatment_line": "first",
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "SSRIs",
      "condition_name": "major depressive disorder",
      "relation": "FIRST_LINE_FOR",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "SSRIs",
      "span": "Therefore, most guidelines currently recommend SSRIs as the first-line treatment for patients with major depression[25].",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "SSRIs",
      "condition_name": "depression",
      "relation": "EQUIVALENT_TO",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "SSRIs",
      "span": "In most systematic reviews and meta-analyses, SSRIs have demonstrated comparable efficacy to TCAs[18,19,29], and there is no significant evidence indicating the superiority of any other class or agent over SSRIs[29-31].",
      "confidence": 1.0,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "venlafaxine",
      "condition_name": "depression",
      "relation": "EQUIVALENT_TO",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Norepinephrine reuptake inhibitors",
      "span": "Also, venlafaxine's efficacy is comparable to that of TCAs.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "reboxetine",
      "condition_name": "depression",
      "relation": "ASSOCIATED_WITH_SE",
      "outcome": null,
      "side_effects": [
        "poor tolerance"
      ],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Norepinephrine reuptake inhibitors",
      "span": "However, these findings could be due to the relatively poor tolerance of reboxetine.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "trazodone",
      "condition_name": "depression",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Other antidepressants",
      "span": "Trazodone is the oldest medication of the so-called 'other antidepressants' group that is still in wide use. It has been shown to be an effective antidepressant in placebo-controlled research.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "nefazodone",
      "condition_name": "depression",
      "relation": "EQUIVALENT_TO",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Other antidepressants",
      "span": "Nefazodone's structure is analogous to that of trazodone, though it has different pharmacological properties. Its efficacy and overall tolerability are comparable to those of SSRIs, as indicated by comparative trials.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "bupropion",
      "condition_name": "major depressive disorder",
      "relation": "EQUIVALENT_TO",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Other antidepressants",
      "span": "However, for individuals with low to moderate levels of anxiety, the efficacy of bupropion in treating MDD is comparable to that of SSRIs.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": "low to moderate levels of anxiety",
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "vortioxetine",
      "condition_name": "depression",
      "relation": "IMPROVES",
      "outcome": "cognitive impairment",
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Other antidepressants",
      "span": "However, they appear to produce less sexual dysfunction and, in the specific case of vortioxetine, have particular benefits in depression-related cognitive impairment.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "trazodone",
      "condition_name": "depression",
      "relation": "ASSOCIATED_WITH_SE",
      "outcome": null,
      "side_effects": [
        "high dropout rates",
        "nausea",
        "vomiting",
        "sexual dysfunction",
        "sedation",
        "priapism",
        "cardiotoxicity"
      ],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Other antidepressants",
      "span": "whereas amitriptyline, clomipramine, duloxetine, fluvoxamine, trazodone, and venlafaxine had the highest dropout rates because of their more frequent and severe side effects. Nausea and vomiting were the most common reasons for treatment discontinuation; sexual dysfunction, sedation, priapism, and cardiotoxicity were also reported.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "ketamine",
      "condition_name": "depression",
      "relation": "ASSOCIATED_WITH_SE",
      "outcome": null,
      "side_effects": [
        "drug abuse",
        "addiction"
      ],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Ketamine and related molecules",
      "span": "Lastly, since ketamine is associated with a higher risk of drug abuse and addiction, it cannot be recommended in daily clinical practice.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "imipramine",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [
        "cardiovascular toxicity",
        "anticholinergic side effects",
        "risk of lethal toxicity from overdoses"
      ],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Perspectives",
      "span": "Imipramine, approved in 1959, demonstrated efficacy in patients with more severe symptoms of major depressive disorder but is associated with cardiovascular toxicity and anticholinergic side effects. There is also a risk of lethal toxicity from overdoses.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "desipramine",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [
        "cardiovascular toxicity",
        "anticholinergic side effects",
        "risk of lethal toxicity from overdoses"
      ],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Perspectives",
      "span": "Desipramine, approved in 1959, showed efficacy in patients with more severe symptoms of major depressive disorder but is associated with cardiovascular toxicity and anticholinergic side effects. There is also a risk of lethal toxicity from overdoses.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "nortriptyline",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [
        "cardiovascular toxicity",
        "anticholinergic side effects",
        "risk of lethal toxicity from overdoses"
      ],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Perspectives",
      "span": "Nortriptyline demonstrated efficacy in patients with more severe symptoms of major depressive disorder but is associated with cardiovascular toxicity and anticholinergic side effects. There is also a risk of lethal toxicity from overdoses.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "amitriptyline",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [
        "cardiovascular toxicity",
        "anticholinergic side effects",
        "risk of lethal toxicity from overdoses"
      ],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Perspectives",
      "span": "Amitriptyline, approved in 1961, demonstrated efficacy in patients with more severe symptoms of major depressive disorder but is associated with cardiovascular toxicity and anticholinergic side effects. There is also a risk of lethal toxicity from overdoses.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "psychotherapy",
      "condition_name": "depression",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "PSYCHOTHERAPY",
      "span": "Psychotherapy for patients with depression strengthens the therapeutic alliance and enables the patient to monitor their mood, improve their functioning, understand their symptoms better, and master the practical tools they need to cope with stressful events.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "cognitive-behavioral therapy",
      "condition_name": "major depressive disorder",
      "relation": "FIRST_LINE_FOR",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Overview of psychotherapy in depression",
      "span": "Depression-focused psychotherapy is typically considered the initial treatment method for mild to moderate MDD. Based on significant clinical evidence, two specific psychotherapeutic methods are recommended: Cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT).",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "interpersonal therapy",
      "condition_name": "major depressive disorder",
      "relation": "FIRST_LINE_FOR",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Overview of psychotherapy in depression",
      "span": "Depression-focused psychotherapy is typically considered the initial treatment method for mild to moderate MDD. Based on significant clinical evidence, two specific psychotherapeutic methods are recommended: Cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT).",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "mindfulness-based cognitive therapy",
      "condition_name": "major depressive disorder",
      "relation": "MAINTENANCE_FOR",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Overview of psychotherapy in depression",
      "span": "After remission, CBT, PEI, and mindfulness-based cognitive therapy (MBCT) are proposed to maintain and prevent depression.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "cognitive behavioral analysis system of psychotherapy",
      "condition_name": "chronic depression",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Overview of psychotherapy in depression",
      "span": "The European Psychiatric Association recommends using the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) for treating chronic depression and utilizing specific approaches suited to each patient's preferences.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "acceptance and commitment therapy",
      "condition_name": "major depressive disorder",
      "relation": "PREVENTS_RELAPSE_IN",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Structured psychotherapies",
      "span": "Acceptance and commitment therapy appears to be effective in reducing depressive symptoms and preventing relapses.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "psycho-education",
      "condition_name": "depression",
      "relation": "IMPROVES",
      "outcome": "clinical course, treatment adherence, psychosocial functioning",
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Other psycho-interventions",
      "span": "Many studies have highlighted the role of psycho-education in improving the clinical course, treatment adherence, and psychosocial functioning in patients with depression.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "ECT",
      "condition_name": "resistant depression",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "SOMATIC TREATMENTS",
      "span": "ECT is the most well-known treatment for resistant depression, and solid evidence supports its effectiveness and safety.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "repetitive transcranial magnetic stimulation (rTMS)",
      "condition_name": "depression",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "SOMATIC TREATMENTS",
      "span": "In recent decades, various innovative techniques have been proposed, such as repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), and magnetic seizure therapy, with varying efficiency levels.",
      "confidence": 0.7,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "transcranial direct current stimulation (tDCS)",
      "condition_name": "depression",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "SOMATIC TREATMENTS",
      "span": "In recent decades, various innovative techniques have been proposed, such as repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), and magnetic seizure therapy, with varying efficiency levels.",
      "confidence": 0.7,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "vagus nerve stimulation (VNS)",
      "condition_name": "depression",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "SOMATIC TREATMENTS",
      "span": "In recent decades, various innovative techniques have been proposed, such as repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), and magnetic seizure therapy, with varying efficiency levels.",
      "confidence": 0.7,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "deep brain stimulation (DBS)",
      "condition_name": "depression",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "SOMATIC TREATMENTS",
      "span": "In recent decades, various innovative techniques have been proposed, such as repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), and magnetic seizure therapy, with varying efficiency levels.",
      "confidence": 0.7,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "magnetic seizure therapy",
      "condition_name": "depression",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "SOMATIC TREATMENTS",
      "span": "In recent decades, various innovative techniques have been proposed, such as repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), and magnetic seizure therapy, with varying efficiency levels.",
      "confidence": 0.7,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "ECT",
      "condition_name": "major unipolar depression",
      "relation": "SUPERIOR_TO",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "ECT",
      "span": "ECT is arguably the most effective treatment modality in psychiatry, and its superiority over pharmacotherapy for major unipolar depression is widely supported.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "rTMS",
      "condition_name": "depression",
      "relation": "IMPROVES",
      "outcome": "improvements in depressive symptoms",
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "rTMS",
      "span": "Recent literature shows a significant difference between rTMS and fictitious stimulation regarding its improvements in depressive symptoms.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "controlled",
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "rTMS",
      "condition_name": "depression",
      "relation": "AUGMENTS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "rTMS",
      "span": "Preliminary research has revealed synergistic (e.g., rTMS/quetiapine) interactions between neuro-modulation and pharmacotherapy.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "preliminary research",
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "rTMS",
      "condition_name": "depression",
      "relation": "EQUIVALENT_TO",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "rTMS",
      "span": "Treatments combining rTMS and antidepressants are significantly more effective than placebo conditions, with mild side effects and good acceptability.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "controlled",
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "tDCS",
      "condition_name": "unipolar depression",
      "relation": "IMPROVES",
      "outcome": "response and remission rate",
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "tDCS",
      "span": "The tDCS technique significantly outperforms the simulator in terms of the rate of response and remission. It can be used as a complementary intervention or as monotherapy to reduce depressive symptoms in unipolar or bipolar depression patients.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "controlled",
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "tDCS",
      "condition_name": "bipolar depression",
      "relation": "IMPROVES",
      "outcome": "response and remission rate",
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "tDCS",
      "span": "The tDCS technique significantly outperforms the simulator in terms of the rate of response and remission. It can be used as a complementary intervention or as monotherapy to reduce depressive symptoms in unipolar or bipolar depression patients.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "controlled",
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "VNS",
      "condition_name": "resistant depression",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "VNS",
      "span": "VNS is a therapeutic method that has been used for the last sixteen years to treat resistant unilateral or bipolar depression. However, despite several clinical studies attesting to its favorable benefit-risk ratio and its approval by the Food Drug Administration in 2005, it is not used very often.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "clinical studies",
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "VNS",
      "condition_name": "resistant depression",
      "relation": "EFFECTIVE_IN_SUBGROUP",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "VNS",
      "span": "Since the turn of the century, numerous studies have demonstrated the efficacy of VNS in resistant depression.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "numerous studies",
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "VNS",
      "condition_name": "resistant depression",
      "relation": "IMPROVES",
      "outcome": "depressive symptoms",
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "VNS",
      "span": "VNS has demonstrated progressively increasing improvements in depressive symptoms, with significant positive outcomes observed after six to 12 mo; these benefits can last for up to two years.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": "6 to 12 months",
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "DBS of the subgenual cingulate white matter",
      "condition_name": "resistant depression",
      "relation": "IMPROVES",
      "outcome": "clinical response",
      "side_effects": [],
      "effect_size": "60% response rate",
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "DBS",
      "span": "According to the literature, DBS of the subgenual cingulate white matter (Brodmann area = BA 25) elicited a clinical response in 60% of resistant depression patients after six months and clinical remission in 35% of patients, with benefits maintained for over 12 mo.",
      "confidence": 1.0,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": "6 months",
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "DBS of the subgenual cingulate white matter",
      "condition_name": "resistant depression",
      "relation": "IMPROVES",
      "outcome": "clinical remission",
      "side_effects": [],
      "effect_size": "35% remission rate",
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "DBS",
      "span": "According to the literature, DBS of the subgenual cingulate white matter (Brodmann area = BA 25) elicited a clinical response in 60% of resistant depression patients after six months and clinical remission in 35% of patients, with benefits maintained for over 12 mo.",
      "confidence": 1.0,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": "6 months",
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "rTMS",
      "condition_name": "depression",
      "relation": "WELL_TOLERATED_IN",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "Luxtherapy (phototherapy)",
      "span": "rTMS is an interesting technique as well, as it offers a well-tolerated profile.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "observational",
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "ECT",
      "condition_name": "certain forms of depression",
      "relation": "MAINTENANCE_FOR",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "discussion",
      "span": "ECT is the only somatic treatment with confirmed indications for certain forms of depression.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "combinations of medications, psychotherapy, and somatic therapies",
      "condition_name": "resistant forms of depression",
      "relation": "EFFECTIVE_IN_SUBGROUP",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "WJCC",
      "section": "discussion",
      "span": "Combinations of medications, psychotherapy, and somatic therapies remain the most effective ways to manage resistant forms of depression.",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    }
  ],
  "total_facts": 49,
  "validation_summary": {
    "original_count": 51,
    "valid_count": 49,
    "invalid_count": 2,
    "warning_count": 0
  }
}